Kaposi's Sarcoma

Oncology
4
Pipeline Programs
4
Companies
45
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/TenofovirPhase 4Small Molecule
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
50 mg/m2 aldoxorubicinPhase 21 trial
Active Trials
NCT02029430Completed15Est. Apr 2016
Pfizer
PfizerNEW YORK, NY
1 program
1
MaravirocPhase 25 trials
Active Trials
NCT02625207Completed47Est. Mar 2016
NCT01894776Completed15Est. Feb 2015
NCT01367236Completed60Est. Oct 2015
+2 more trials
PTC Therapeutics
1 program
1
VEGF inhibitor PTC299Phase 1/21 trial
Active Trials
NCT00686842Terminated17Est. Dec 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc
PfizerMaraviroc

Showing 15 of 45 trials with date data

Clinical Trials (45)

Total enrollment: 7,238 patients across 45 trials

NCT01367236PfizerMaraviroc

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Start: Jan 2013Est. completion: Oct 201560 patients
Phase 4Completed
NCT01384682PfizerMaraviroc

Maraviroc Switch Collaborative Study

Start: Aug 2011Est. completion: Dec 2015399 patients
Phase 4Completed
NCT01275625PfizerMaraviroc

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Start: Jun 2011Est. completion: Jul 201398 patients
Phase 4Completed
NCT01327547PfizerMaraviroc

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Start: May 2011Est. completion: Mar 2015138 patients
Phase 4Completed
NCT01013987PfizerMaraviroc

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Start: Feb 201060 patients
Phase 4Unknown
NCT00782301PfizerMaraviroc

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Start: Mar 2009Est. completion: Feb 20100
Phase 4Withdrawn
NCT00925756PfizerMaraviroc

CCR5 Inhibitor Treatment Intensification on CD4+ T-cell Recovery

Start: Oct 2008Est. completion: Apr 201432 patients
Phase 4Completed
NCT00735072PfizerMaraviroc

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

Start: Sep 2008Est. completion: Jul 201045 patients
Phase 4Completed
NCT00717067PfizerMaraviroc

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Start: Jul 2008Est. completion: Nov 200830 patients
Phase 4Completed
NCT00853840PfizerMaraviroc

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Start: Apr 2008Est. completion: May 200818 patients
Phase 4Completed
NCT00666705PfizerMaraviroc

A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects

Start: Feb 2008Est. completion: Mar 200818 patients
Phase 4Completed
NCT01345630PfizerMaraviroc

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Start: Sep 2011Est. completion: Jan 2014813 patients
Phase 3Terminated
NCT01348308PfizerMaraviroc

Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

Start: Sep 2011Est. completion: Mar 2016407 patients
Phase 3Completed
NCT00844519PfizerMaraviroc

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

Start: Jan 2010Est. completion: Jun 201452 patients
Phase 3Completed
NCT00719823PfizerMaraviroc

Maraviroc Compassionate Use

Start: Aug 2008Est. completion: May 20100
Phase 3Withdrawn
NCT00478231PfizerMaraviroc

Multicenter, Safety Study Of Maraviroc

Start: Jul 2007Est. completion: Sep 2010209 patients
Phase 3Completed
NCT00098293PfizerMaraviroc

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Start: Nov 2004Est. completion: Dec 2012916 patients
Phase 3Completed
NCT00098722PfizerMaraviroc

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects

Start: Dec 2004Est. completion: Apr 2011474 patients
Phase 2/3Completed
NCT00098748PfizerMaraviroc

Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects

Start: Nov 2004Est. completion: Apr 2009190 patients
Phase 2/3Completed
NCT02029430ImmunityBio50 mg/m2 aldoxorubicin

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

Start: Apr 2014Est. completion: Apr 201615 patients
Phase 2Completed
NCT01276236PfizerMaraviroc

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

Start: Mar 2011Est. completion: Apr 201513 patients
Phase 2Completed
NCT00993148PfizerMaraviroc

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Start: May 2010Est. completion: Apr 201325 patients
Phase 2Completed
NCT00987948PfizerMaraviroc

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Start: Jan 2010Est. completion: Aug 201315 patients
Phase 2Completed
NCT00944541PfizerMaraviroc

Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration

Start: Sep 2009Est. completion: Jan 201160 patients
Phase 2Completed
NCT00827112PfizerMaraviroc

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Start: Mar 2009Est. completion: Jul 2011129 patients
Phase 2Completed
NCT00795444PfizerMaraviroc

Effect Of A CCR5 Coreceptor Antagonist On The Latency And Reservoir Of HIV-1

Start: Mar 2008Est. completion: Jan 201510 patients
Phase 2Completed
NCT00634959PfizerMaraviroc

Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Start: Jul 2003Est. completion: Dec 200337 patients
Phase 2Completed
NCT00643643PfizerMaraviroc

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Start: Oct 2002Est. completion: Jun 200341 patients
Phase 2Completed
NCT00686842PTC TherapeuticsVEGF inhibitor PTC299

PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma

Start: Sep 2008Est. completion: Dec 201017 patients
Phase 1/2Terminated
NCT02625207PfizerMaraviroc

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Start: Nov 2015Est. completion: Mar 201647 patients
Phase 1Completed
NCT01894776PfizerMaraviroc

A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc

Start: Jun 2013Est. completion: Feb 201515 patients
Phase 1Completed
NCT01597895PfizerMaraviroc

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Start: Jul 2012Est. completion: Aug 201214 patients
Phase 1Completed
NCT01290211PfizerMaraviroc

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Start: Apr 2011Est. completion: Jun 201128 patients
Phase 1Completed
NCT01133210PfizerMaraviroc

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Start: Jan 2011Est. completion: Nov 201227 patients
Phase 1Completed
NCT01140412PfizerMaraviroc

Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

Start: Jul 2010Est. completion: Oct 201014 patients
Phase 1Terminated
NCT01056874PfizerMaraviroc

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Start: Mar 2010Est. completion: Apr 201012 patients
Phase 1Completed
NCT00821535PfizerMaraviroc

Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers

Start: Feb 2009Est. completion: May 200912 patients
Phase 1Completed
NCT00783484PfizerMaraviroc

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

Start: Oct 2008Est. completion: May 200937 patients
Phase 1Completed
NCT00703586PfizerMaraviroc

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Start: Sep 2007Est. completion: May 20118 patients
Phase 1Completed
NCT00496782PfizerMaraviroc

Multicenter Pilot Study To Define The Marker As An Alternate For Tropism Assay

Start: Jul 2007Est. completion: Oct 200816 patients
Phase 1Terminated
NCT00864474PfizerMaraviroc

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

Start: Mar 2010Est. completion: Dec 201868 patients
N/ACompleted
NCT00801515PfizerMaraviroc

A Compassionate Access Protocol For Those Patients Who Have Completed A4001029

Start: Aug 2009Est. completion: Jul 2011
N/ANo Longer Available
NCT00850395PfizerMaraviroc

Non-Interventional Study Of Celsentri® In Treatment Experienced Patients With CCR5-Tropic HIV-Infection

Start: Jul 2009Est. completion: Oct 201179 patients
N/ACompleted
NCT00665561PfizerMaraviroc

Prospective Observational Epidemiologic Study of Maraviroc's Safety

Start: Mar 2008Est. completion: Feb 20192,500 patients
N/ACompleted
NCT00525733PfizerMaraviroc

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Start: Oct 2007Est. completion: Dec 201340 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)